Table 2.
Variable | n (%) | CEP17 Status |
P⁎ | ||
---|---|---|---|---|---|
Normal | Duplicated | ||||
CEP17 | 137 | 124 (90.5) | 13 (9.5) | ||
Age, years | ≤ 50 | 65 (47.5) | 61 (49) | 4 (30.8) | .206 |
> 50 | 72 (52.5) | 63 (51) | 9 (69.2) | ||
Menopausal status | Premenopausal | 63 (46) | 59 (47) | 4 (30.8) | .247 |
Postmenopausal | 74 (54) | 65 (53) | 9 (69.2) | ||
Tumor stage | II | 49 (35.8) | 44 (33.5) | 5 (38.5) | .830 |
III | 88 (64.2) | 80 (64.5) | 8 (61.5) | ||
Tumor status | T2 | 38 (27.7) | 33 (27) | 5 (38.6) | .606 |
T3 | 42 (30.7) | 38 (30) | 4 (30.7) | ||
T4 | 57 (41.6) | 53 (43) | 4 (30.7) | ||
Node status | N0 | 46 (33.5) | 42 (34) | 4 (31) | .538 |
N1 | 62 (45.5) | 54 (44) | 8 (61.5) | ||
N2 | 25 (18) | 24 (19) | 1 (7.5) | ||
N3 | 4 (3) | 4 (3) | 0 (0) | ||
Tumor grade | 1 | 11 (8) | 11 (9) | 0 (0) | .499 |
2 | 62 (45) | 55 (44) | 7 (54) | ||
3 | 64 (47) | 58 (47) | 6 (46) | ||
ER | Positive | 86 (62.8) | 77(62) | 9 (69.2) | .613 |
Negative | 51 (37.2) | 47 (38) | 4 (30.8) | ||
PR | Positive | 68 (49.6) | 62 (50) | 6 (46) | .792 |
Negative | 69 (50.4) | 62 (50) | 7 (54) | ||
Ki67 status | < 20% | 73 (53.3) | 66 (53) | 7 (54) | .937 |
≥ 20% | 60 (50.4) | 54 (43.5) | 6 (46) | ||
Missing data | 4 (2.9) | 4 (3) | 0 (0) | ||
HER2 | Normal | 112 (82) | 103 (83) | 9 (69) | .166 |
Amplification | 23 (17) | 19 (15) | 4 (31) | ||
Missing data | 2 (1) | 2 (2) | 0 (0) | ||
TOP2A | Normal | 124 (91) | 111 (89.5) | 13 (100) | .220 |
Amplification | 7 (5) | 7 (5.5) | 0 (0) | ||
Deletion | 6 (4) | 6 (5) | 0 (0) | ||
Neoadjuvant therapy | FEC75/FAC60 | 84 (61.3) | 76 (61) | 8 (61.5) | .986 |
EC-D | 53 (38.7) | 48 (39) | 5 (38.5) | ||
Surgical treatment | Mastectomy | 86 (62.9) | 78 (62.9) | 8 (61.5) | .923 |
Lumpectomy | 51 (37.1) | 46 (37.1) | 5 (38.5) | ||
Pathologic response | Complete | 12 (8.7) | 9 (7.3) | 3 (23) | .055 |
Residual disease | 125 (91.3) | 115 (92.7) | 10 (77) |
P values were calculated using the Chi-square test.